Zentalis Pharmaceuticals’ Joint Venture Zentera Therapeutics

Wilson Sonsini Goodrich & Rosati advised Tybourne Capital Management in the financing.

On May 20, 2020, Zentalis Pharmaceuticals announced the closing of a $20 million Series A financing to establish a Chinese joint venture, Zentera Therapeutics. Tybourne Capital Management, a global investment manager headquartered in Asia, led the financing.

Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, is a majority shareholder of Shanghai, China-based Zentera. Proceeds from the Series A financing will be used to develop and commercialize three cancer therapies discovered by Zentalis, in addition to potential future candidates in China.

The Wilson Sonsini team included partners Dan Koeppen (Picture) and Miranda Biven, and associate Nimish Sheth.

Involved fees earner: Miranda Biven – Wilson Sonsini Goodrich & Rosati; Dan Koeppen – Wilson Sonsini Goodrich & Rosati; Nimish Sheth – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Tybourne capital management;


Author: Ambrogio Visconti